Download PDF
Exp Clin Endocrinol Diabetes 2015; 123(10): 622-626
DOI: 10.1055/s-0035-1559608
Article
© Georg Thieme Verlag KG Stuttgart · New York

Gender-specific Effects of Treatment with Lifestyle, Metformin or Sulfonylurea on Glycemic Control and Body Weight: A German Multicenter Analysis on 9 108 Patients

M. Schütt
1   Department of Internal Medicine I, University of Lübeck, Germany
,
A. Zimmermann
2   Diabetes-Schwerpunktpraxis, Bad Aibling, Germany
,
R. Hood
3   Helios Klinikum Duisburg, Germany
,
M. Hummel
4   Diabetes-Schwerpunktpraxis Rosenheim & Institute of Diabetes Research, Helmholtz Zentrum München, Germany
,
J. Seufert
5   Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Germany
,
E. Siegel
6   St. Josefs Hospital Heidelberg, Department of Internal Medicine, Germany
,
A. Tytko
7   St. Vincenz Hospital, Department of Internal Medicine, Limburg, Germany
,
R. W. Holl
8   Institute of Epidemiology and medical Biometry, University of Ulm, Ulm, Germany
,
for the DPV initiative and the German BMBF Competence Network Diabetes mellitus › Author Affiliations
Further Information

Publication History

received 15 June 2015
first decision 15 June 2015

accepted 15 July 2015

Publication Date:
18 August 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Effects of diabetes treatment are strongly connected to individual factors, but the relevant role of gender has not been addressed so far. This observational study evaluates whether monotherapy with lifestyle, metformin or sulfonylurea has gender-specific effects on glycemic control and/or body weight. Data of 9 108 patients with type 2 diabetes from 129 German diabetes centers were assessed by a standardized, prospective, computer-based diabetes care and outcome documentation system (DPV-Wiss-database; age 63.1±12.8 years, diabetes duration 5.7±7.4 years, HbA1c 55±17.7 mmol/mol [7.2±1.6%], BMI 30.6±6.1 kg/m2, 49.3% female patients). Antidiabetic concepts included lifestyle intervention (n=5,787), metformin (n=2,180), sulfonylurea (n=943) or other antidiabetic drugs (n=198), respectively. HbA1c and body weight were compared before and after a stable monotherapeutical period of 0.8±0.4 years. Women had a significantly higher reduction of body weight after treatment with lifestyle (women−0.8±0.1 vs. men−0.2±0.1 kg; p<0.05), metformin (women−1.8±0.2 vs. men−1.2±0.2 kg; p<0.05) or sulfonylurea drugs (women−0.9±0.2 vs. men − 0.1±0.2 kg; p<0.05), whereas men displayed significantly higher HbA1c-reductions after treatment with lifestyle (women−6.9±0.2 mmol/mol [− 0.6±0.02%] vs. men−7.5±0.2 mmol/mol [0.7±0.02%]; p<0.05) and metformin only (women−6.3±0.3 mmol/mol [− 0.6±0.03%] vs. men − 7.4±0.3 mmol/mol [− 0.7±0.03%]; p<0.05). No differences were seen for sulfonylurea monotherapy concerning the HbA1c-reduction (women − 5.6±0.5 mmol/mol [− 0.5±0.05%] vs. men−6.4±0.4 mmol/mol [− 0.6±0.04%]; p=0.196). In summary, antidiabetic treatment concepts might result in gender-specific effects on body weight and HbA1c. Gender might therefore represent another important factor in the context of an individualized treatment management of type 2 diabetes.

Key words

type 2 diabetes - diabetes treatment - gender - body weight - glycemic control
 

  • References

  • 1 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596
    CrossrefPubMedGoogle Scholar
  • 2 Melloni C, Berger JS, Wang TY et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010; 3: 135-142
    CrossrefPubMedGoogle Scholar
  • 3 Mosca L, Banka CL, Benjamin EJ et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol 2007; 49: 1230-1250
    CrossrefPubMedGoogle Scholar
  • 4 Zhang Y, Zitsman JL, Hou J et al. Fat cell size and adipokine expression in relation to gender, depot, and metabolic risk factors in morbidly obese adolescents. Obesity 2014; 22: 691-697
    CrossrefPubMedGoogle Scholar
  • 5 Legato MJ, Gelzer A, Goland R et al. Writing group for the partnership for gender-specific medicine. Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 2006; 3: 131-158
    CrossrefPubMedGoogle Scholar
  • 6 Schunk M, Reitmeir P, Schipf S et al. Health-related quality of life in subjects with and without Type 2 diabetes: Pooled analysis of five population-based surveys in Germany. Diabetic Medicine 2012; 29: 646-653
    CrossrefPubMedGoogle Scholar
  • 7 Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-78
    CrossrefPubMedGoogle Scholar
  • 8 Göbl CS, Brannath W, Bozkurt L et al. Sex-specific differences in glycemic control and cardiovascular risk factors in older patients with insulin-treated type 2 diabetes mellitus. Gend Med 2010; 7: 593-599
    CrossrefPubMedGoogle Scholar
  • 9 Kautzky-Willer A, Handisurya A. Metabolic diseases and associated complications: Sex and gender matter. Eur J Clin Invest 2009; 39: 631-648
    CrossrefPubMedGoogle Scholar
  • 10 Booth GL, Kapral MK, Fung K et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368: 29-36
    CrossrefPubMedGoogle Scholar
  • 11 Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431-1437
    CrossrefPubMedGoogle Scholar
  • 12 Bilezikian JP, Josse RG, Eastell R et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: 1519-1528
    CrossrefPubMedGoogle Scholar
  • 13 Geerlings S, Fonseca V, Castro-Diaz D et al. Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 2014; 103: 373-381
    CrossrefPubMedGoogle Scholar
  • 14 Schütt M, Fach EM, Seufert J et al. DPV Initiative and the German BMBF Competence Network Diabetes Mellitus. Multiple complications and frequent severe hypoglycaemia in ‘elderly’ and ‘old’ patients with Type 1 diabetes. Diabet Med 2012; 29: e176-e179
    CrossrefPubMedGoogle Scholar
  • 15 Hanas R, John G. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 2010; 33: 1903-1904
    CrossrefPubMedGoogle Scholar
  • 16 Westfall PH, Tobias RD, Wolfinger RD. Multiple comparisons and multiple tests using SAS. 2nd Edition SAS Institute; 2011
    Google Scholar
  • 17 Golay A. Metformin and body weight. Int J Obes 2008; 32: 61-72
    CrossrefPubMedGoogle Scholar
  • 18 Morrison F, Shubina M, Turchin A. Lifestyle counseling in routine care and long-term glucose, blood pressure, and cholesterol control in patients with diabetes. Diabetes Care 2012; 35: 334-341
    CrossrefPubMedGoogle Scholar
  • 19 Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care 2001; 24: 561-587
    CrossrefPubMedGoogle Scholar
  • 20 Mittendorfer B, Magkos F, Fabbrini E et al. Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity 2009; 17: 1872-1877
    CrossrefPubMedGoogle Scholar
  • 21 Held C, Iqbal R, Lear SA et al. Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. Eur Heart J 2012; 33: 452-466
    CrossrefPubMedGoogle Scholar
  • 22 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885
    CrossrefPubMedGoogle Scholar
  • 23 DECODE Study Group . Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003; 26: 61-69
    CrossrefPubMedGoogle Scholar
  • 24 Anderwald C, Tura A, Winhofer Y et al. Glucose absorption in gestational diabetes mellitus during an oral glucose tolerance test. Diabetes Care 2011; 34: 1475-1480
    CrossrefPubMedGoogle Scholar
  • 25 Zhou K, Donnelly L, Yang J et al. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2014; 2: 481-487
    PubMedGoogle Scholar
  • 26 Williams LK, Padhukasahasram B, Ahmedani BK et al. Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab 2014; 99: 3160-3168
    CrossrefPubMedGoogle Scholar
  • 27 Selvin E, Bolen S, Yeh HC et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070-2080
    CrossrefPubMedGoogle Scholar
  • 28 Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol 2010; 44: 87-97
    CrossrefPubMedGoogle Scholar
  • 29 Lyons MR, Peterson LR, McGill JB et al. Impact of sex on the heart’s metabolic and functional responses to diabetic therapies. Am J Physiol Heart Circ Physiol 2013; 305: H1584-H1591
    CrossrefPubMedGoogle Scholar